Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
作者： Yukari Umeyama , Yasushi Fujioka , Teruaki Okuda
DOI: 10.3109/00498254.2014.928958
关键词:
摘要: Abstract1. Recently, the Food and Drug Administration (FDA) European Medicines Agency have shown decision trees to determine whether a drug candidate is an inhibitor of P-glycoprotein (P-gp). However, there has been no clear information on P-gp inhibition can be significant in clinical drug–drug interactions (DDIs). The purpose this study was confirm effect through comprehensive analysis DDI studies.2. Clinical collected using University Washington Metabolism Transport Interaction Database™. risks inhibition-related were qualitatively evaluated terms contribution CYP3A inhibition. degrees risk categorized area under plasma concentration–time curve increase ratio (AUCR), according FDA criteria.3. When both inhibited, potent 25% studies. When did not contribute ...
informahealthcare.com参考文章(123)
H Rameis, Quinidine-digoxin interaction: are the pharmacokinetics of both drugs altered? International journal of clinical pharmacology, therapy, and toxicology. ,vol. 23, pp. 145- 153 ,(1985)
Jens Rengelshausen, Christoph Göggelmann, Jürgen Burhenne, Klaus-Dieter Riedel, Jochen Ludwig, Johanna Weiss, Gerd Mikus, Ingeborg Walter-Sack, Walter E. Haefeli, Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. British Journal of Clinical Pharmacology. ,vol. 56, pp. 32- 38 ,(2003) , 10.1046/J.1365-2125.2003.01824.X
Shingen Misaka, Nozomu Miyazaki, Midori S. Yatabe, Tomoyuki Ono, Yayoi Shikama, Tetsuhito Fukushima, Junko Kimura, Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. The Journal of Clinical Pharmacology. ,vol. 53, pp. 738- 745 ,(2013) , 10.1002/JCPH.95
Sebastian Härtter, Regina Sennewald, Gerhard Nehmiz, Paul Reilly, Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects. British Journal of Clinical Pharmacology. ,vol. 75, pp. 1053- 1062 ,(2013) , 10.1111/J.1365-2125.2012.04453.X
Xavier Delavenne, Edouard Ollier, Thierry Basset, Laurent Bertoletti, Sandrine Accassat, Arnauld Garcin, Silvy Laporte, Paul Zufferey, Patrick Mismetti, A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. British Journal of Clinical Pharmacology. ,vol. 76, pp. 107- 113 ,(2013) , 10.1111/BCP.12055
Stephen C. Olson, Paul H. Siedlik, Bing Bing Yang, Ralph H. Stern, Erythromycin coadministration increases plasma atorvastatin concentrations. The Journal of Clinical Pharmacology. ,vol. 39, pp. 501- 504 ,(1999) , 10.1177/009127009903900510
M Kaijser, Emöke Dimeny, Bengt Fellstrom, Lilian Zezina, Ulla Backman, C Johnsson, Elevation of cyclosporin A blood levels during carvedilol treatment in renal transplant patients. Clinical Transplantation. ,vol. 11, pp. 577- 581 ,(1997)
Laura J. Cabelus, Guy W. Amsden, George Foulds, Anne N. Nafziger, A study of the pharmacokinetics of azithromycin and nelfinavir when coadministered in healthy volunteers. The Journal of Clinical Pharmacology. ,vol. 40, pp. 1522- 1527 ,(2000) , 10.1177/009127000004001226
Jennifer Lee, Selina Moy, John Meijer, Walter Krauwinkel, Taiji Sawamoto, Virginie Kerbusch, Donna Kowalski, Michael Roy, Alan Marion, Shin Takusagawa, Marcel van Gelderen, James Keirns, Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clinical Drug Investigation. ,vol. 33, pp. 429- 440 ,(2013) , 10.1007/S40261-013-0084-Y
Anders Asberg, Anders Hartmann, Ellen Fjeldsa, Stein Bergan, Hallvard Holdaas, Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients American Journal of Transplantation. ,vol. 1, pp. 382- 386 ,(2001) , 10.1034/J.1600-6143.2001.10415.X